{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:20:58Z","timestamp":1783110058631,"version":"3.54.6"},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Nanocarriers are these days considered an attractive approach in cancer\nimmunotherapy owing to their ability to deliver antigens to antigen-presenting cells (APCs) for\nstimulating robust immune cells against the tumor.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The objective of this study was to construct nanocomplexes using two nanocarriers with\nnegative surface charge, adenovirus (Ad) and human serum albumin nanoparticle (HSA-NP), and\ncoat their surface with a modified and positively-charged HPV16 E7 MHC-I specific epitope to assess\ntheir anti-tumor effects in a TC-1 mouse model.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>After the construction of Ad and HSA-NP, their complexes with HPV16 E7 MHC-I specific\nepitope were characterized by zeta potential and dynamic light scattering. Then, the cellular\nimmunity and CTL responses in immunized mice were assessed by measuring the levels of IL-10\nand IFN-\u03b3 and the expression of CD107a, a marker of CTL response, as well as tumor inhibition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The zeta potential and dynamic light scattering results showed that incubation of the oppositely-\ncharged nanocarriers and MHC-I specific epitope led to the formation of nanocomplexes in\nwhich the surface charge of nanocarriers was changed from negative to positive with minimal\nchanges in the particle size. We demonstrated that the nanocomplex platforms in heterologous primeboost\nregimens generate significantly higher E7-specific IL-10, IFN-\u03b3, and CTL responses. Moreover,\nthe heterologous nanocomplex regimens, Alb\/Pep-Ad\/Pep and Ad\/Pep-Alb\/Pep, significantly\nsuppressed the growth of TC-1 tumors in vivo compared with mice receiving homologous regimens\nand naked nanocarriers.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The heterologous nanocomplexes might serve as an effective vaccine strategy against\nHPV-induced cervical cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201023666220922122531","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:29:43Z","timestamp":1663907383000},"page":"1195-1203","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heterologous Prime-boost Vaccination Using Adenovirus and Albumin\nNanoparticles as Carriers for Human Papillomavirus 16 E7 Epitope"],"prefix":"10.2174","volume":"24","author":[{"given":"Momeneh","family":"Ghanaat","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hami","family":"Kaboosi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Negahdari","sequence":"additional","affiliation":[{"name":"Department of Medical\nBiotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail","family":"Fattahi","sequence":"additional","affiliation":[{"name":"Department of Biology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziba Veisi","family":"Malekshahi","sequence":"additional","affiliation":[{"name":"Department of Medical\nBiotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25136","volume":"9","author":"Br&#xFC;ggmann D.","year":"2018","unstructured":"Br&#xFC;ggmann D.; Kayser L.; Jaque J.; Bundschuh M.; Klingelh&#xF6;fer D.; Groneberg D.A.; Human papilloma virus: Global research architecture assessed by density-equalizing mapping. Oncotarget 2018,9(31)","journal-title":"Oncotarget"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41401-021-00616-5","volume":"42","author":"Ghanaat M.","year":"2021","unstructured":"Ghanaat M.; Goradel N.H.; Arashkia A.; Ebrahimi N.; Ghorghanlu S.; Malekshahi Z.V.; Fattahi E.; Negahdari B.; Kaboosi H.; Virus against virus: Strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol Sin 2021,42(12),1981-1990","journal-title":"Acta Pharmacol Sin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygyno.2019.12.017","volume":"156","author":"Clark K.T.","year":"2020","unstructured":"Clark K.T.; Trimble C.L.; Current status of therapeutic HPV vaccines. Gynecol Oncol 2020,156(2),503-510","journal-title":"Gynecol Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","volume":"26","author":"Hoppe-Seyler K.","year":"2018","unstructured":"Hoppe-Seyler K.; Bossler F.; Braun J.A.; Herrmann A.L.; Hoppe-Seyler F.; The HPV E6\/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol 2018,26(2),158-168","journal-title":"Trends Microbiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13402-011-0069-x","volume":"35","author":"Ganguly N.","year":"2012","unstructured":"Ganguly N.; Human papillomavirus-16 E5 protein: Oncogenic role and therapeutic value. Cell Oncol 2012,35(2),67-76","journal-title":"Cell Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s12272-017-0952-8","volume":"40","author":"Kim H.J.","year":"2017","unstructured":"Kim H.J.; Kim H.J.; Current status and future prospects for human papillomavirus vaccines. Arch Pharm Res 2017,40(9),1050-1063","journal-title":"Arch Pharm Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/vaccines2030515","volume":"2","author":"Li W.","year":"2014","unstructured":"Li W.; Joshi M.; Singhania S.; Ramsey K.; Murthy A.; Peptide vaccine: Progress and challenges. Vaccines 2014,2(3),515-536","journal-title":"Vaccines"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.vaccine.2004.05.022","volume":"23","author":"Fifis T.","year":"2004","unstructured":"Fifis T.; Mottram P.; Bogdanoska V.; Hanley J.; Plebanski M.; Short peptide sequences containing MHC class I and\/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004,23(2),258-266","journal-title":"Vaccine"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.2147\/IJN.S194352","volume":"14","author":"Lee S.J.","year":"2019","unstructured":"Lee S.J.; Kim J.J.; Kang K.Y.; Paik M.J.; Lee G.; Yee S.T.; Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin. Int J Nanomedicine 2019,14,8235-8249","journal-title":"Int J Nanomedicine"},{"key":"ref=10","first-page":"1095","volume":"14","author":"Selvaraja V.K.","year":"2020","unstructured":"Selvaraja V.K.; Gudipudi D.K.; Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. Ecancer med. Sci 2020,14,1095","journal-title":"Sci"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.597806","volume":"8","author":"Thakur N.","year":"2020","unstructured":"Thakur N.; Thakur S.; Chatterjee S.; Das J.; Sil P.C.; Nanoparticles as smart carriers for enhanced cancer immunotherapy. Front Chem 2020,8","journal-title":"Front Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1016\/j.vaccine.2010.09.077","volume":"28","author":"Hirosue S.","year":"2010","unstructured":"Hirosue S.; Kourtis I.C.; van der Vlies A.J.; Hubbell J.A.; Swartz M.A.; Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 2010,28(50),7897-7906","journal-title":"Vaccine"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/2326-6066.CIR-18-0166","volume":"6","author":"Galliverti G.","year":"2018","unstructured":"Galliverti G.; Tichet M.; Domingos-Pereira S.; Hauert S.; Nardelli-Haefliger D.; Swartz M.A.; Hanahan D.; Wullschleger S.; Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. Cancer Immunol Res 2018,6(11),1301-1313","journal-title":"Cancer Immunol Res"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1105429","volume":"5","author":"Capasso C.","year":"2016","unstructured":"Capasso C.; Hirvinen M.; Garofalo M.; Romaniuk D.; Kuryk L.; Sarvela T.; Vitale A.; Antopolsky M.; Magarkar A.; Viitala T.; Suutari T.; Bunker A.; Yliperttula M.; Urtti A.; Cerullo V.; Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. OncoImmunology 2016,5(4)","journal-title":"OncoImmunology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1158\/1535-7163.MCT-15-0559","volume":"15","author":"Garofalo M.","year":"2016","unstructured":"Garofalo M.; Iovine B.; Kuryk L.; Capasso C.; Hirvinen M.; Vitale A.; Yliperttula M.; Bevilacqua M.A.; Cerullo V.; Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity. Mol Cancer Ther 2016,15(4),651-660","journal-title":"Mol Cancer Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3389\/fimmu.2018.02968","volume":"9","author":"Xiang S.D.","year":"2018","unstructured":"Xiang S.D.; Wilson K.L.; Goubier A.; Heyerick A.; Plebanski M.; Design of peptide-based nanovaccines targeting leading antigens from gynecological cancers to induce HLA-A2. 1 restricted CD8+ T cell responses. Front Immunol 2018,9,2968","journal-title":"Front Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.02.003","volume":"541","author":"Luis de Red&#xED;n I.","year":"2018","unstructured":"Luis de Red&#xED;n I.; Boiero C.; Mart&#xED;nez-Oh&#xE1;rriz M.C.; Ag&#xFC;eros M.; Ramos R.; Pe&#xF1;uelas I.; Allemandi D.; Llabot J.M.; Irache J.M.; Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm 2018,541(1-2),214-223","journal-title":"Int J Pharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/laban.254","volume":"42","author":"Faustino-Rocha A.","year":"2013","unstructured":"Faustino-Rocha A.; Oliveira P.A.; Pinho-Oliveira J.; Teixeira-Guedes C.; Soares-Maia R.; da Costa R.G.; Cola&#xE7;o B.; Pires M.J.; Cola&#xE7;o J.; Ferreira R.; Ginja M.; Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim 2013,42(6),217-224","journal-title":"Lab Anim"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1128\/IAI.01459-08","volume":"77","author":"de Alencar B.C.G.","year":"2009","unstructured":"de Alencar B.C.G.; Persechini P.M.; Haolla F.A.; de Oliveira G.; Silverio J.C.; Lannes-Vieira J.; Machado A.V.; Gazzinelli R.T.; Bruna-Romero O.; Rodrigues M.M.; Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 2009,77(10),4383-4395","journal-title":"Infect Immun"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1074\/jbc.272.10.6479","volume":"272","author":"Fasbender A.","year":"1997","unstructured":"Fasbender A.; Zabner J.; Chill&#xF3;n M.; Moninger T.O.; Puga A.P.; Davidson B.L.; Welsh M.J.; Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997,272(10),6479-6489","journal-title":"J Biol Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"62214","DOI":"10.1039\/C5RA08501B","volume":"5","author":"Kamali M.","year":"2015","unstructured":"Kamali M.; Dinarvand R.; Maleki H.; Arzani H.; Mahdaviani P.; Nekounam H.; Adabi M.; Khosravani M.; Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma. RSC Advances 2015,5(76),62214-62219","journal-title":"RSC Advances"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1016\/j.vaccine.2007.05.040","volume":"25","author":"Toubaji A.","year":"2007","unstructured":"Toubaji A.; Hill S.; Terabe M.; Qian J.; Floyd T.; Simpson R.M.; Berzofsky J.A.; Khleif S.N.; The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007,25(31),5882-5891","journal-title":"Vaccine"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0929-6646(10)60017-4","volume":"109","author":"Lin K.","year":"2010","unstructured":"Lin K.; Doolan K.; Hung C.F.; Wu T.C.; Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010,109(1),4-24","journal-title":"J Formos Med Assoc"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.gt.3301251","volume":"7","author":"Geutskens S.B.","year":"2000","unstructured":"Geutskens S.B.; van der Eb M.M.; Plomp A.C.; Jonges L.E.; Cramer S.J.; Ensink N.G.; Kuppen P.J.K.; Hoeben R.C.; Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther 2000,7(16),1410-1416","journal-title":"Gene Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","volume":"11","author":"Coughlan L.","year":"2020","unstructured":"Coughlan L.; Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front Immunol 2020,11,909","journal-title":"Front Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"11241","DOI":"10.1128\/JVI.00721-06","volume":"80","author":"Tamanini A.","year":"2006","unstructured":"Tamanini A.; Nicolis E.; Bonizzato A.; Bezzerri V.; Melotti P.; Assael B.M.; Cabrini G.; Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006,80(22),11241-11254","journal-title":"J Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"11627","DOI":"10.1128\/JVI.79.18.11627-11637.2005","volume":"79","author":"Schoggins J.W.","year":"2005","unstructured":"Schoggins J.W.; Nociari M.; Philpott N.; Falck-Pedersen E.; Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J Virol 2005,79(18),11627-11637","journal-title":"J Virol"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119971","volume":"591","author":"Zhou Y.C.","year":"2020","unstructured":"Zhou Y.C.; Zhang Y.N.; Yang X.; Wang S.B.; Hu P.Y.; Delivery systems for enhancing oncolytic adenoviruses efficacy. Int J Pharm 2020,591","journal-title":"Int J Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"Danaei M.","year":"2018","unstructured":"Danaei M.; Dehghankhold M.; Ataei S.; Hasanzadeh Davarani F.; Javanmard R.; Dokhani A.; Khorasani S.; Mozafari M.; Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018,10(2),57","journal-title":"Pharmaceutics"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1021\/nl803487r","volume":"9","author":"Cho E.C.","year":"2009","unstructured":"Cho E.C.; Xie J.; Wurm P.A.; Xia Y.; Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2\/KI etchant. Nano Lett 2009,9(3),1080-1084","journal-title":"Nano Lett"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/smll.201100001","volume":"7","author":"Zhao F.","year":"2011","unstructured":"Zhao F.; Zhao Y.; Liu Y.; Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011,7(10),1322-1337","journal-title":"Small"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nantod.2016.04.008","volume":"11","author":"Wang H.X.","year":"2016","unstructured":"Wang H.X.; Zuo Z.Q.; Du J.Z.; Wang Y.C.; Sun R.; Cao Z.T.; Ye X.D.; Wang J.L.; Leong K.W.; Wang J.; Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines. Nano Today 2016,11(2),133-144","journal-title":"Nano Today"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","volume":"32","author":"Xiao K.","year":"2011","unstructured":"Xiao K.; Li Y.; Luo J.; Lee J.S.; Xiao W.; Gonik A.M.; Agarwal R.G.; Lam K.S.; The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011,32(13),3435-3446","journal-title":"Biomaterials"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0939-6411(98)00038-1","volume":"46","author":"Roser M.","year":"1998","unstructured":"Roser M.; Fischer D.; Kissel T.; Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998,46(3),255-263","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/mp800032f","volume":"5","author":"Dobrovolskaia M.A.","year":"2008","unstructured":"Dobrovolskaia M.A.; Aggarwal P.; Hall J.B.; McNeil S.E.; Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008,5(4),487-495","journal-title":"Mol Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/molecules27020403","volume":"27","author":"Khan M.A.","year":"2022","unstructured":"Khan M.A.; Malik A.; Alzohairy M.A.; Alruwetei A.M.; Alhatlani B.Y.; Rugaie O.A.; Khan A.; Liposome-mediated delivery of MERS antigen induces potent humoral and cell-mediated immune response in mice. Molecules 2022,27(2),403","journal-title":"Molecules"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1061186X.2022.2066681","author":"Khan M.A.","year":"2022","unstructured":"Khan M.A.; Malik A.; Alruwetei A.M.; Alzohairy M.A.; Alhatlani B.Y.; Al Rugaie O.; Alhumaydhi F.A.; Khan A.; Delivery of MERS antigen encapsulated in &#x3B1;-GalCer-bearing liposomes elicits stronger antigen-specific immune responses. J Drug Target 2022,1-10","journal-title":"J Drug Target"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2249.2006.03065.x","volume":"144","author":"Lin T.","year":"2006","unstructured":"Lin T.; Liang S.; Meng F.; Han Q.; Guo C.; Sun L.; Chen Y.; Liu Z.; Yu Z.; Xie H.; Ding J.; Fan D.; Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin Exp Immunol 2006,144(2),319-325","journal-title":"Clin Exp Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.biomaterials.2012.12.030","volume":"34","author":"Lemke C.D.","year":"2013","unstructured":"Lemke C.D.; Geary S.M.; Joshi V.B.; Salem A.K.; Antigen-coated poly &#x3B1;-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations. Biomaterials 2013,34(10),2524-2529","journal-title":"Biomaterials"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.omto.2020.10.001","volume":"19","author":"Ring S.S.","year":"2020","unstructured":"Ring S.S.; Kr&#xF3;lik M.; Hartmann F.; Schmidt E.; Hasan Ali O.; Ludewig B.; Kochanek S.; Flatz L.; Heterologous prime boost vaccination induces protective melanoma-specific CD8+ T cell responses. Mol Ther Oncolytics 2020,19,179-187","journal-title":"Mol Ther Oncolytics"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/S0264-410X(01)00086-X","volume":"19","author":"van der Burg S.H.","year":"2001","unstructured":"van der Burg S.H.; Kwappenberg K.M.C.; O\u2019Neill T.; Brandt R.M.P.; Melief C.J.M.; Hickling J.K.; Offringa R.; Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001,19(27),3652-3660","journal-title":"Vaccine"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-005-0700-7","volume":"55","author":"Mackova J.","year":"2006","unstructured":"Mackova J.; Stasikova J.; Kutinova L.; Masin J.; Hainz P.; Simsova M.; Gabriel P.; Sebo P.; Nemeckova S.; Prime\/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006,55(1),39-46","journal-title":"Cancer Immunol Immunother"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220922122531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209098\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220922122531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:49:31Z","timestamp":1691426971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209098\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201023666220922122531","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}